Ingredion Incorporated
INGRConsumer DefensiveNASDAQPackaged Foods
Scan Results
Daily timeframeHeadquartered within the consumer defensive sector, Ingredion Incorporated focuses on Packaged Foods services and products. Ingredion Incorporated, together with its subsidiaries, engages in the manufacture and sale of sweeteners, starches, nutrition ingredients, and biomaterial solutions derived from wet milling and. With a market capitalization of $6.04B, it sits in mid-cap territory. The company operates in Texture & Healthful Solutions; Food & Industrial IngredientsLATAM; and Food & Industrial IngredientsU.S./CANADA segments.
Market Cap
$6.04B
Beta
0.64
P/E (TTM)
10.41
P/E (Fwd)
8.52
EPS (TTM)
$9.19
EPS (Fwd)
$11.23
ROE
13.7%
ROA
7.3%
Cash
$952.0M
Total Debt
$1.78B
Free CF
$457.2M
52W Change
-18.5%
Annual Financials
Cash vs Debt
Where INGR stands vs its 150-day and 200-day moving averages
As of the October 8, 2026 close, INGR finished 8.25% below its 150-day moving average ($102.73) and 10.36% below its 200-day moving average ($105.14). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is INGR overbought or oversold?
At the October 8, 2026 close, INGR's RSI(14) was 30.5, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, INGR has $952.0M in cash with $1.78B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $457.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 13.7%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 7.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $7.95B (2022) to $7.22B (2025).
INGR's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing INGR.